Controversy Surrounds Abortion Pill Decision and FDA Support
TL;DR
Pfizer CEO Albert Bourla signed a letter along with over 200 pharmaceutical company executives in support of the FDA's authority to regulate drugs after a federal judge in Texas suspended the agency's approval of the abortion pill mifepristone. The executives raised concerns that the ruling will set a precedent for diminishing the FDA's authority over drug approvals, which would create uncertainty for the entire industry. The dueling orders by two federal judges create a complicated legal standoff that could potentially escalate to the Supreme Court.
- Pfizer CEO signs letter in support of FDA after federal judge suspends approval of abortion pill CNBC
- AOC doubles down on 'ignoring' abortion rule, Clarence Thomas impeachment: 'abuse of judicial overreach' Fox News
- Ohioans’ access to abortion pill in question after Texas judge orders ban NBC4 WCMH-TV
- Opinion | I Worked at the F.D.A. The Abortion Pill Decision Is Dangerous. The New York Times
- Opinion | The Abortion Pill Ruling Is Bad Law, and the Biden Administration Should Fight It The New York Times
Want the full story? Read the original reporting
Read on CNBC